Wednesday, November 11, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

The Most Active Startup Acquirers Of The Past 3 Years Aren’t Always Who You’d Expect

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: The Most Active Startup Acquirers Of The Past 3 Years Aren’t Always Who You’d Expect Date: 2026-03-20 11:00 Source: https://news.crunchbase.com/ma/most-active-startup-acquirers-3-years-crm-openai-snowflake/ <p>Companies that buy a lot of startups don’t always have a lot in common.</p…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Salesforce, OpenAI and Snowflake are the most prolific acquirers of seed- and venture-backed startups in recent years

    60% confidence

  • The pace of startup M&A dealmaking remains fairly robust in 2026

    60% confidence

  • Salesforce has purchased at least 91 companies in the past 20 years

    60% confidence

  • Six companies made six or more known purchases in the past three years

    60% confidence

  • OpenAI has bought 16 companies in the past three years

    60% confidence

  • 79 companies acquired three or more seed- or venture-backed startups in the past three years

    60% confidence

  • The AI sector's appetite for acqui-hires and smaller purchases of earlier-stage startups continues to boost momentum

    60% confidence

  • Snowflake has 19 acquisitions to date

    60% confidence

Data points we hold from this source

OpenAI · total acquisitions16 companies
Salesforce · total acquisitions91 companies
Snowflake Inc. · total acquisitions19 companies
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
The Most Active Startup Acquirers Of The Past 3 Years Aren’t Always Who You’d Expect — Source | Via News | Via News